StoneRidge PMG Advisors, LLC’s Esperion Therapeutics ESPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-18,237
Closed -$58K – 152
2026
Q2
$58K Buy
+18,237
New +$51K 0.04% 143
2024
Q4
– Sell
-117,958
Closed -$195K – 151
2024
Q3
$195K Hold
117,958
– – 0.07% 94
2024
Q2
$262K Buy
117,958
+24,557
+26% +$57.8K 0.1% 97
2024
Q1
$250K Buy
93,401
+64,145
+219% +$156K 0.1% 95
2023
Q4
$87K Hold
29,256
– – 0.04% 88
2023
Q3
$29K Hold
29,256
– – 0.01% 99
2023
Q2
$41K Buy
+29,256
New +$40.8K 0.02% 106

Other funds holding ESPR

StoneRidge PMG Advisors, LLC's ESPR Position: Q3 2026 in Review

StoneRidge PMG Advisors, LLC sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 18,237 shares — an estimated $58K sold.

StoneRidge PMG Advisors, LLC first reported a position in ESPR in Q2 2023 and held it in 7 quarters. The position peaked at $262K in Q2 2024. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

  • StoneRidge PMG Advisors, LLC reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
  • StoneRidge PMG Advisors, LLC sold 18,237 Esperion Therapeutics shares in Q3 2026, an estimated $58K.
  • StoneRidge PMG Advisors, LLC first reported a position in Esperion Therapeutics in Q2 2023 and held it in 7 quarters.
  • StoneRidge PMG Advisors, LLC's Esperion Therapeutics position peaked at $262K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on StoneRidge PMG Advisors, LLC's 13F filing for Q3 2026, filed 4 Nov 2026.